Silliman C C, Dickey W O, Paterson A J, Thurman G W, Clay K L, Johnson C A, Ambruso D R
Department of Pediatrics, University of Colorado School of Medicine, Denver, USA.
Transfusion. 1996 Feb;36(2):133-9. doi: 10.1046/j.1537-2995.1996.36296181925.x.
Compounds generated during the routine storage of platelet concentrates may have deleterious effects on the transfusion recipient.
Daily plasma samples from platelet concentrates, both apheresis platelets and those separated from whole blood, were obtained serially during routine storage. These plasma samples were assayed for their ability to prime the NADPH oxidase in isolated human neutrophils. Quantitative and qualitative analysis of the priming agents was completed by lipid extraction, high-pressure liquid chromatography separation, and gas chromatography/mass spectroscopy.
Compounds were generated in both apheresis and whole-blood platelets that significantly primed the NADPH oxidase after 24 and 48 hours of storage, respectively. The priming activity was maximal by component outdate: 2.6-fold that of the buffer-treated control neutrophils (apheresis) and 3.9-fold that of the buffer-treated control neutrophils (whole blood). These agents were generated by cellular constituents, as stored plasma did not demonstrate such priming activity. Inhibition of this priming activity by WEB 2170, a specific platelet-activating factor receptor antagonist, suggested that the observed priming involved the platelet-activating factor receptor. A portion of the priming activity from platelet concentrates was organically extractable: 69 percent of that from apheresis platelets and 46 percent of that from whole-blood platelets. Further purification of the lipid's priming activity by normal-phase high-pressure liquid chromatography demonstrated a single peak of priming activity at the retention time of lysophosphatidylcholines. Because 46 percent of the priming activity from whole-blood platelets was chloroform insoluble and because it has been reported that interleukin 8 is generated during routine storage of whole-blood platelets, the effects of interleukin 8 on the NADPH oxidase were examined. Recombinant monocyte interleukin 8 rapidly primed the oxidase but was not inhibited by WEB 2170.
Lipids were generated during the routine storage of platelet concentrates that prime the NADPH oxidase, and they may play a role in the severe complications of transfusion therapy. Other non-lipid compounds, such as interleukin 8, that are generated in whole-blood platelets may also contribute to the observed priming activity of plasma.
血小板浓缩物在常规储存过程中产生的化合物可能对输血受者产生有害影响。
在常规储存期间,连续获取来自单采血小板和从全血中分离的血小板浓缩物的每日血浆样本。对这些血浆样本进行检测,以评估其引发分离的人中性粒细胞中NADPH氧化酶的能力。通过脂质提取、高压液相色谱分离和气相色谱/质谱法对引发剂进行定量和定性分析。
单采血小板和全血血小板在储存24小时和48小时后分别产生了能显著引发NADPH氧化酶的化合物。按成分过期时引发活性最高:是缓冲液处理的对照中性粒细胞(单采血小板)的2.6倍,是缓冲液处理的对照中性粒细胞(全血)的3.9倍。这些物质由细胞成分产生,因为储存的血浆未显示出这种引发活性。特异性血小板活化因子受体拮抗剂WEB 2170对这种引发活性的抑制表明,观察到的引发涉及血小板活化因子受体。血小板浓缩物的一部分引发活性可通过有机溶剂提取:单采血小板的为69%,全血血小板的为46%。通过正相高压液相色谱对脂质的引发活性进行进一步纯化,在溶血磷脂酰胆碱的保留时间处显示出一个引发活性的单峰。由于全血血小板46%的引发活性不溶于氯仿,且据报道全血血小板在常规储存期间会产生白细胞介素8,因此研究了白细胞介素8对NADPH氧化酶的影响。重组单核细胞白细胞介素8能迅速引发氧化酶,但不受WEB 2170抑制。
血小板浓缩物在常规储存过程中产生的脂质可引发NADPH氧化酶,它们可能在输血治疗的严重并发症中起作用。全血血小板中产生的其他非脂质化合物,如白细胞介素8,也可能导致观察到的血浆引发活性。